Lexicon Pharmaceuticals (LXRX) PT Lowered to $5 at Leerink Partners
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Lexicon Pharmaceuticals (LXRX) PT Lowered to $6 at H.C. Wainwright
November 1, 2024 6:39 AM EDT(Updated - November 1, 2024 6:40 AM EDT)
H.C. Wainwright analyst Joseph Pantginis lowered the price target on Lexicon Pharmaceuticals (NASDAQ: LXRX) to $6.00 (from $10.00) while maintaining a Buy rating.
The analyst commented: "Yesterday, the AdCom for sotagliflozin in T1D+CKD was... More
Lexicon Pharma (LXRX) Halted, News Pending
October 31, 2024 7:01 AM EDTLexicon Pharma (NASDAQ: LXRX) Halted, News Pending
... More